share in fourth finish including today momentum our everyone. quarter. strong a pleased GENETICS, XXXX I tremendous you was year to Thank the to SOPHiA you, and built a Katherine. the good for am that we period, morning, And with
XXXX year into I and call, as growth the acceleration On will whole our we QX. and today's throughout experienced a review the organic year
strategic fiscal operating Then company our discipline our discussion as focus I will about executed deliverables as touch GENETICS, demonstrated with to areas at ecosystem third back a thoughts and consecutive a share partnerships about leverage. wrap my our for key software I XXXX, of you by by fuel globally. and provide then in our into with up improved will the Financial upon the that we Next, SOPHiA to tie will participants quarter guiding on financial our trajectory look I preferred platform taking turn your our for questions. analytics outlook and six pillars Officer, towards end SOPHiA's Ross cloud-native for healthcare it the detailed we will being a our over long-term will results period and Chief XXXX, more Muken,
being Officer. who, me join in Ross. being ever congratulating Please March addition in is promoted Congratulations, Chief XXXX XX, to Operating Ross to of capable as CFO,
Let the to course multiple their be genomics. market; biopharma; especially their business learning algorithms beyond beyond and clinical, anonymized SOPHiA data in be of that their AI profile would machine applicable would US the that company. with you deliver expectation had that to while three me model investors major decentralized is questions the for were: start its GENETICS' expectation on us reminding questions The public, SOPHiA three SOPHiA GENETICS while and far genomic show value GENETICS just able could as Europe, clinical compatible collected have GENETICS one two, in SOPHiA when across a successful line so for was would top by SOPHiA went three, commitment, One, demonstrate to growth modalities
and three while a questions, marketplace. to demonstrated momentum year, delivered this all would capital only have volatile today to can the both unexpected all answer constrained also given not commitments, our growth that, we challenges I having confidently yes have we suggest a overcome the associated on but with macroenvironment
significant in these on incremental a finding costs. achieving are challenges efficiencies without and stride both on committed SOPHiA have expectations growth to incurring in at and taken we our So, lofty sustainable and fashion
adjusting constant by growth Let currency growth XXXX constant long-term me XX%. was headwinds. of this achievement. in revenue success. basis growth strongest acknowledging on proud guidance constant XX% to full-year Full-year XX%, our line after of am robust we COVID-related a of of with currency revenue evidence the XXXX, start for In delivered XX% I our incredibly currency
in should I introduced impacting our COVID-XX we customers. that you remind to XXXX, pandemic our the solution in response QX global
we reasonable COVID Given shifted laboratories this, within XXXX a platform. testing their efforts our of initiatives, results, to as address our accommodate, versatility our of help thereby analysis demonstrating had which impact customers global were on able to the some
disease R&D rare core of we our our applications. in XXXX, decided to focus back oncology towards and shift
for related growth our robust So, pleased adjusting that we are of COVID-XX XXXX, as XXXX a was, I XX%. in the impact quite headwinds in stated,
market a strong consider choose medicine Why cloud-based many standard as such to institutions Healthcare as having are their for challenging? GENETICS during would trusted platform SOPHiA adoption a care. period their we establishing driven analytics data of continue
more our are In customers, that in customers. am more we XXX thrilled XXX customers XXXX, platform across DDM SOPHiA signed than XX also to customers announce served recurring XXXX. we countries. I new XXX Of XX than
continued where complex data the sets the helping produced impact, inform greatest our During can the generation SOPHiA's clinicians in it diseases. This from happens next cloud to through improve ability cancer to in positioning rare determination sequencers. have the of we and their platform year, handle market of to
large, incredibly up an types often that multiple Our be many and are heterogeneous environment, data terabytes different can X from suppliers. potentially customers what The are to producing noisy, sets is of sequencers, at lab using production chemistry locally in using our raw customers size.
algorithms, We code that and trained DDM onto our and From essence, their SOPHiA the artificial cloud intelligence up upload the is our proprietary founding. years over our customers which, we have machine XX labs, from our those in based learning built files platform. meticulously since disease-specific then apply sequencer decentralized
pathologists our in and the or find which will sauce, we noisy huge signals the if harmonize secret geneticists annotate access relevant It SOPHiA the is identify through this and will, genomic you DDM. with biomarkers, have code, and the that file and to
to over patients of XXXX, algorithms instantaneously. as rare profile the cancer is and incrementally realizable because genomic our nearly XX, are our December million robust. network cloud each become disease benefits global more X.X And we based, With analyzed,
cloud [Technical to up Our year-over-year. design XX% Difficulty]
I to has the DDM platform. per We're date, million excited genomics Importantly, for users SOPHiA month. recently by value platform as highlight than X.X makes This, utilization XX,XXX the increase that, the their the SOPHiA profiles, than after experiencing more we think, with supported industry us profiles momentum of growing want you more the analysis new leader. see DDM of we continue the to to
in is desired ASP. lift areas ASP. an saw expected in high, increase price above This a we and and in helping are our As from beyond of where with higher we benefits our it's that expected is example more shifts overall XXXX. focus technology mix a one the complexities product surprise towards mid-year is that, HRD no notably the took XXXX,
focus this an rare is and carry value to each reported strategic diseases This or mix through, of important we increase analysis evident our expect phenomenon, to analysis on our idea revenue time. oncology So cadence healthy growth over a outpacing as is the growth. the in volume at patient
guidance out you want the that we how While I to over on of played discussed our also picture how for for I year. draw XXXX, the delivered
the growth, of for revenue analysis, to our margins, ex-COVID of of XXXX, finishing accelerating the accelerated in year fourth full-year margin We XXXX that quarter suggest strategic fourth that and first And gross revenue a the currency constant high each path quarter XX%. the target XX% strong. are ended with gross results figures, quarter compared XXXX, year closer pleased quarter. to at the long with us growth XX% our XX% growth volume, of for increasingly is share adjusted in term bringing our These year-over-year to
to focus focus, been the a our capital of new desire in to XXXX. expenses course, make three cash each flex is We of efficiency. operating While a expenses best and equal Reducing performance intend of our has top advance the use the to reduced last of ability our line in and discipline challenge we the year, to balance. of has, muscle operating to of fiscal optimizing continue been our keen solve quarters our learned
been to very our indirect control have We costs. precise, intending
targeted also all. We programs, maintaining projects, not key of but sponsorship
our in benefit cost execution of revenue delivered am So, we of I say on summary, a added proud material have discipline. with to commitment
So, remarks, outstanding we several when were public, opening my suggested questions. as there went in I
decentralized respect GENETICS' Kettering the to proof point of that With first Center. we market. of the Cancer (MSK) major The Memorial compatibility model question, Sloan let SOPHiA in expand are proud on relationship is me and with XXXX the one our new super US in
combining of patients. expertise Considered the power that one diverse test an liquid DDM reach into with oncology GENETICS agreement platform. United advanced cancer powered the comprehensive a genomics, our we global MSK the of jointly centers States, cancer the commercialize biopsy will SOPHiA SOPHiA we By clinical in of first envision where entered predictive we precision will the population most global by algorithms in the of cancer tools network more and prominent
into to for implementing is turning to be sciences to SOPHiA They deeper I DDM of at state's like US University the momentum, health Next, malignancies. university. a recent Arkansas only Arkansas. will UAMS, highlight would of hematological customer the University gain Medical win insights Sciences,
group synthesize time, fast to nature enable expertise the fourth are cancers hematological leukemia, together of SOPHiA for improved most such is type the turnaround materially as data and or myeloma, as on crucial allowing moving will NGS DDM cancer a given building in-house, that of them malignancies local which frequent lymphoma, multiple globally. data
fourth SOPHiA Arkansas, forefront a They Beyond they in which could full their the for in using diagnostic menu we because US accelerate Mobile, platform service DDM quarter. use offering felt we Synergy hereditary them patient University our the Labs, would to outcome. help highlight will cancer to hereditary They be Alabama, of solution. of the based decided I cancer also signed lab
typical have maintain. the unique. use The from machine in NGS each off-the-shelf clients suppliers each are also solutions our is bit software of manufacturer coming a for specific lab. as or difficult a many lab is that either Synergy multiple would they machine, central NGS and expensive scale by specialized off Normally, lab leading homegrown data that sold of to sequencers to
software for such library code software automation environment, to competitors' typically compatibility respect files struggles this various of regions, heterogeneous tools. the or with in prep limited the a as The has oftentimes programs output
the data heterogeneous SOPHiA a is unique We key the challenge harmonize through for regardless customers source region's of signals of to DDM. this environment in in innovative It our SOPHiA sequencer. platform's the and differentiator lab the capability solve at
back accurate the of at we results the in tie data heterogeneous like in lowest years So, if environments to I both confidently to doing and Synergy, and the after for helps them. Synergy, solution Synergy deliver market refinement, cost. so, manner genomic a winning this most This secure US code digest from and able development us XX a may and are is
in progress forward to continuous on America our progress. with pleased our am North and I in total, XXXX In updating you look
And data question, for show our some of especially and our biopharma we not value profile second to clinical, source has produced locally could as customers? competition do, beyond the genomic our anonymized that purchased, at
the we insight. when silo When and data in we data this, variability pharmaceutical thought world reconciling their disparate These data similar felt high companies in clinical with about the challenges real space regarding faced sources. trial result of challenges that to clinical quality
world. customers and, the by across in them to call DDM chain, ultimately, from real biopharma by the are our which this development real drug the to biopharma our data and aligning SOPHiA serve We generated applications time all and value We development the in powered product, bottlenecks solve continuum of address deployment. services XDs, helping discovery
We launched currently for our in biopharma applications have biopharma customers. we XXXX for branded initial four applications the market and
the question, value show to to to able back is SOPHiA So, biopharma?
our the our AstraZeneca announcement point partnership. will And yes. this opinion February you demonstrates a on is is I that that expanding proof resounding my tell
now was We on AstraZeneca's testing on deployment with them phase. discovery. our with support. in the working Then, there, started we and working are relationship AZ worldwide from This taking with HRD built
Now be could how oncology on SOPHiA's and collaborating leading multimodal AstraZeneca's expertise be we technology portfolio. to global applied will
benefit of have. as companies the we we're CROs we they Astra, today of platform argue many in world because as the top our pharma well data the understand network, XX with and our in Beyond would leading conversation over the half
see we biopharma different clinical have we customers, behavior they expect the new same but in and they will With follow start points with may space. the SOPHiA, land expand
diagnostic first method is Bio therapies extra routine Extra next of with precision around amplified along of Boundless announced chromosome, Beyond oncogene biopharma a of more the DNA in exciting players, chromosomal those patient's cancer. biotech involves oncology a chromosomal Bio a with we Boundless to ecDNA data. innovative September very a DNA release outside therapeutics the metastatic regarding found traditional and developing is in from technology company, or working against are is cancer. we that developing detect precision XX% ecDNA. Boundless Bio generation ecDNA DNA directed in sequencing to in
develop Our clinical further method partnership will in diagnostic trials. for use this
drug lead major to to and combined new global clinical unlock barrier breaking decentralized hospitals solution collective to deliver our inherent genomics cancers. and central lab Our the by traditional with This should and a value to to development Boundless effectively of amplified optimized design, Bio oncogene trial treatment centers patient network options selection enable academic with approach. capabilities patients global
And data as beyond say, is that, we always important.
access to the Now are SOPHiA cancer democratize use the globe. genomic to Kettering, with incremental types. Sloan over clinical XX,XXX going will profiles medicine Memorial of curated around applications across we DDM have Together, precision
from data, to have felt to data other have capabilities laboratory data. should the we beyond felt over gathered me imaging, be generated address clinical question, let just patients. From insight from our the our benefit improve on, out genomic that our the beyond of for not and genomics that, applied from the but Now, of viability we time, when Intuitively, early predictive modalities data further genomics. of also platform third modalities algorithms
flagship and us, study, data, cell tell December such this will of cancer data. which of DEEP-Lung-IV approaches in immunotherapy. data, multimodal of metastatic delivered world a radiomic of The XXXX. across launched our concept with promise the is I focuses for cancer including we treatment in genomic clinical we proof range The DEEP-Lung-IV data clinical patients multi-modality of has multimodal biological aggregate the strong types. you, study real on data, non-small multimodal context, And lung example
validate response These are enabled at patients to the signatures of ensure patients validated words leverages survival survival. of level, deep supporting analysis right for signatures patient supporting aim clinical the progression ultimately are selected and transparency learning predictive or its of to decisions multimodal their predictive aggregation therapy, then technology Our the the of overall and to individual of drivers with make free real data biopharma being the informed to clinicians full on with prediction, for identify trial. the
potential of at an reported, of set validates third in a preliminary ASCO predictive setting. We multimodal decentralized XXXX, the of for multicentric XX%, us international suggesting around which results, a our power and approach
applicability with of that This is typically level important are of limitations regarding similar and models highly studies scalability at as center strong done these institution. today, multimodal the outside the single particular
world Through patients to diverse and the expand to learning global for Dasa up we Latin exposed sites context, currently our date. participation a US, machine our Brazil the that France, sites. footprint that of of in recruited this wide America to through already algorithms, now data. very several with Germany, across In Spain, report exposure Brazil, continue algorithms signed range real process our Israel, Canada, of Italy, DEEP-Lung-IV X,XXX multimodal around study, aim we with to collaboration this have XX footprint, intentional to maximize are also are with happy we with in now being There the in from to participating our activating data
to this a that Additionally, produce data. technologies set us exposes of diverse footprint that
further the data demonstrating our in SOPHiA standardized thousands of in offer unique to data in different medical well MRI, from scanners a setting, images positioning and our imaging is platform example, from analytics different This PET decentralized For as generated to market and imaging as harmonized manufacturers. DDM modality, gives us technology-agnostic capability analytics the a CT, platform. exposed
accelerate segments not lesions partner, to are We and medical DEEP-Lung-IV to of the used Healthcare, towards annotate analytics move our allows the imaging working study, study lung quantification. in workflows tumor This automatic body only the context and GENETICS proposals. segmentation identification, for where fabric GE's to particular the annotation are radiomics and imaging GE in whole context in proprietary of further with services visualize SOPHiA visualization
validating We a the a the to patient fact, single In DEEP-Lung-IV at of We vision that collective visualization, in a medicine to module of DDM applications level. on to multimodal capabilities would data generate real the the usher from world has our further that solution. feel multimodal DEEP-Lung-IV, potential look prediction purpose offering one building in the new multimodal platform, at patient we'll forward SOPHiA level. individual generation novel coding predictive precision insights intelligence, of for enable of individual the and leveraging decentralized study advanced power data the
I share am on in to happy growth progress of total, So, our to we that make deliver continued commitments and across our all key drivers.
What a I paramount our flex on as to key IPO to learned reducing muscle fiscal us is in As operating apparent earlier, the since expenses environment XXXX. is discipline global how is. touched deteriorated became our we
growth, minimize we a mindset. reduction any challenge on intention at operating of impact precision to set expense our with With the this
am to I the our expenses, subsequent were improvement that, most of the reduce quarter. each pleased able in fourth quarter in to significant in we report cumulating XXXX, operating
a stands planned reduction continue making at December cash balance. actions regarding as of XXX. our XXXX, use XXX and fiscal XX, intend productivity. Our to liabilities aimed This headcount primarily efficient high furthering selective We at of from best and down improving discipline our has over occurred through the related of
Based trajectory, remain in we see growth capital on current confident sufficient execute our position our to continue runway our and plan. ambitious to
and responsive macroenvironment We sustainable current continue on laser be growth. and to focused delivering remain the to operating
the efficiency Layered been capital on capitalizing thinking of our has partners. commercial on into leverage
can and with trusting to leverage grow. others mindset Our of this we was other understand MSK to thrilled center how cancer are than ourselves, about felt rather our already technology spoke partnership you caliber property. place, us now us with help intellectual we I we doing everything in could and their
the we collaborations, with spark a our of we more existing strengthening provide and than GE innovation Through Qiagen could we volume AstraZeneca, more Healthcare, individually. partnership offer and our large XXXX, with capabilities of connect continued increase data quickly, scale strategic collaborators. size In network, other and
to that feat. I a enjoy the for and But data that with brings demonstrate in And on Scaling Microsoft concept, multimodal partnerships would in several scale Microsoft infrastructure Microsoft a we the capture as highlight serve points detail. support of leverage. of all capability. We to significant partner, multimodal you capability. these very small will to well one their like and is no will take understand Microsoft. as SOPHiA important. is us of moment intersecting we cloud
four you walk me it months in our through first since Let November. announcing
steering included the operational Lead Healthcare two high Microsoft Incubation. These held strategic Microsoft US, Healthcare between Vice of President innovation General Manager Microsoft committee well Senior alignment meetings and levels have Strategy, the We workstream. including as and commercial meetings meetings the companies, on in and for at Business Strategy Industry for as
currently our The focus is and to commercial Microsoft our expanding an our environment our supporting program. the with Nuance increased of DEEP-Lung-IV by strategic scaling CarePath program, + scaled Microsoft threefold, collaboration accelerate reach
pleased to in is force help will XX DDM I report been on to and target Microsoft sales as selling ultimately market. our our sales will amplify the am Microsoft over have market. person be SOPHiA trained This meaningful presence
reminding I creation value are our would pillars, strategic which driving six and GENETICS. They follows. you like focus customers, SOPHiA wrap remain and growth for partners up our our for of long-term as by to at shareholders
DEEP-Lung-IV current measure, expansion with XX with our accelerating network discussed and participating sites today the a note market. of Synergy of of On University this focus being recent with study, on also highlighting would customers in adoption and the wins I we US. traction, X our One, Arkansas. US customer clinical have new
our more XX% base. use three customer or applications Currently, Two, use within only two application, and customers four our use one increasing SOPHiA utilization applications. only of XX% existing or XX%
take our our would respective adopting faster top customers customers. smaller also our Regarding It market. customers to utilization, that share enables see than in share I technology our their to appears that us growth
increase platform capabilities our modules. innovating Kettering a highlighted in portfolio of further and We application growing house to and Memorial call. for you Sloan Three, our today's
key partnerships and Four, ecosystem. our to foster developing collaborations
we the you topic Microsoft On of have our relationship. our leverage to getting ecosystem, from burgeoning highlighted
adoption Five, companies. with biopharmaceutical to drive leveraging our platform further
existing we developments highlighted with AstraZeneca. have our Here,
operating lastly, excelling our within improved despite goals. and trajectory, displayed loss Six top line which our we operationally through hitting SOPHiA,
that I our today be that Regarding the out with MSK, do feel momentum to pillar, in elements partners, our excited SOPHiA set with to outstanding enable beyond. towards patient ago, insights the customer our that data that to execution do meaningfully generate Microsoft, from contribute the for XX more community outcomes Qiagen patient to GENETICS than that deliver and global years these SOPHiA and meaningfully against building that success and to this what will AstraZeneca, performance paired harness we XXXX care contribute actionable are and
With to performance call the that, to more I Ross now our discuss turn in will over financial detail.
